This review (full text) discusses the studies and meta-analyses of adverse cardiovascular events from testosterone replacement therapy. Their conclusion is that no firm conclusion can be gathered from the studies to date.
In summary, the number of cardiovascular events reported in TTrials are low; in fact, it is lower than the expected rate for the age and comorbidities of the participants. None of the trials discussed above was powered to evaluate cardiovascular events and most enrolled a small number of participants, making any small differences between groups inconclusive. ... [The] meta-analyses provide limited information, as they are limited by the fact that most studies included were low-to-medium quality and none was powered to evaluate cardiovascular events. Therefore, firm conclusions regarding the cardiovascular safety of testosterone therapy cannot be drawn from these data.
In summary, the number of cardiovascular events reported in TTrials are low; in fact, it is lower than the expected rate for the age and comorbidities of the participants. None of the trials discussed above was powered to evaluate cardiovascular events and most enrolled a small number of participants, making any small differences between groups inconclusive. ... [The] meta-analyses provide limited information, as they are limited by the fact that most studies included were low-to-medium quality and none was powered to evaluate cardiovascular events. Therefore, firm conclusions regarding the cardiovascular safety of testosterone therapy cannot be drawn from these data.
